Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And that gives us a strong backbone of significant underlying profitability, and we're investing those revenues in a highly focused way to realize our vision and to capitalize on the very significant growth opportunities in front of us |
| In 2023, Genmab made great strides towards our 2030 vision, making for a transformative year in our company's history and on patient care |
| So Jonathan, we feel really confident that we can continue to perform strongly going forward |
| And now that we know more about the profile really the feedback that we’re getting from customers and the enthusiasm based on the reactions they’re seeing with patients around not just the power of the overall responses, but the manageable safety profile and the seamless and efficient step-up dosing and subcutaneous administration as well as reduced patient in-office administration time and efficiency and throughput, we think we’re really well positioned to continue to retain a market leadership position, and we’re really excited about additional launches in the B-cell malignancy space with FL being next on the docket |
| And I would say that the healthy uptick we’ve seen driven really by strong execution gives us a high degree of confidence that we can continue to retain our market leader status, particularly the reactions that we’re getting, the strong access that we’re getting in the U.S |
| So we are going to be very, very critical there, and we have firepower and we have the ability to execute and leverage on the investments we made over the last few years |
| So it’s a sign of strength and confidence in our own ability to further build value to our shareholders |
| And then finally, you could see that as a sign of confidence, we believe that this is the right moment to show really strong confidence in our future and the commitment to deliver value to shareholders |
| Finally, we will continue to leverage our solid financial base to support our growth, including to grow and broaden our exciting product and technology portfolio |
| Genmab has continued to have transformative growth in all areas of our company |
| And our 2024 guidance highlights our highly compelling growth profile |
| Both of these regulatory submissions were supported by the positive results from the confirmatory innovaTV 301 study in cervical cancer |
| In summary, we had a very solid 2023 |
| Taken together, this balanced approach positions us for sustained success and long-term value creation |
| This underscores our confidence in Genmab's future and our commitment to delivering value to shareholders, both in the short and long term |
| Now, as we further built out our development and commercialization capabilities, we are well positioned to also consider development and commercial stage opportunities |
| And this really illustrates the improving quality of our revenue profile |
| For 2024, we anticipate another year of strong underlying revenue growth at 19% |
| So with that background, let's take a look at the components of our strong recurring revenue |
| DARZALEX showed continued strong demand growth in Q4 with over $2.5 billion in net sales, a 22% year-over-year growth and the full year result was over $9.74 billion, driven by volume growth, also a 22% year-on-year growth |
| We're encouraged by the continued market share gains in the first-line setting |
| We anticipate strong growth in revenue and operating profit for 2024 at 19% and 10% at the midpoint, respectively |
| And finally, the significant revenue growth and our continued focused approach to managing our investments translates to a projected double-digit or 10% growth in operating profit at the midpoint of the guidance range |
| So as you can see, continued strong underlying financial performance |
| KESIMPTA achieved continued strong demand growth with $640 million in the quarter and $2.2 billion for the full-year 2023 |
| But that's just one of the exciting opportunities that provide us with a compelling rationale for investing back in our business |
| Overall, our strong recurring revenue growth enables continued highly focused investment, as you can see on the next slide |
| Operational growth in 2023 continued to be strong, driven by higher DARZALEX royalties as well as royalties from other products, and this really illustrates the power of our recurring revenue |
| Our solid balance sheet, growing recurring revenues and significant underlying profitability allow us to continue to invest in our business and our pipeline in a very focused and disciplined way |
| We expect to see continued strong Genmab revenue growth from our diverse royalty medicines portfolio in 2024 |
| Statement |
|---|
| You would also have noted Jonathan, I did highlight in terms of the non-recurring revenue, the step-down being driven by reimbursement revenue declining and that being partially offset by an increase in milestones |
| On the investment side, our OpEx growth is projected to slow down significantly year-over-year |
| The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward-looking statement includes, among other, risks associated with products discovery and development, uncertainties related to the outcome of clinical trials, slower-than-expected rate of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and the markets, our inability to attract and retain suitably qualified personnel, the enforceability or lack of protection of our patents or proprietary rights, our relationships with affiliated entities, changes and developments in technology, which may render our products obsolete, and other factors |
| Really, the question is -- so I'm trying to just piece together the pieces as far as -- you talk about the fact that the reimbursement revenue that you're assuming within 2024, is going to decrease |
| In terms of the reimbursement revenue and what you're pointing out, that number coming down, but investment in 1042 and 1046 and other BioNTech partnered programs going up, this is all true and both true at the same time |
| The decrease is primarily related to lower reimbursement revenue |
| We went straight into the head to head because that’s really irrelevant |
| This has been possible because of what makes us unique |
| So clearly, this is a significant reduction in both percentage terms and absolute Danish kroner terms |
Please consider a small donation if you think this website provides you with relevant information